Pooled adverse events with administration of the NVX-CoV2373 vaccine versus placebo, stratified by age of clinical trial participants

Table 10.6-3. Pooled adverse events with administration of the NVX-CoV2373 vaccine versus placebo, stratified by age of clinical trial participants
Adverse events within 7 days of administration from studies 2019n-501, -301, and -302; study participants aged 18-64 years
Adverse event reported	Dose 1 (%)	Dose 2 (%)
Local tenderness	50.7	69.3
Local erythema	1.0	6.3
Local swelling	0.9	5.8
Pain at injection site	35.2	57.7
Fatigue	24.9	46.8
Headache	25.3	43.4
Nausea or vomiting	6.7	11.3
Fever	0.6	5.7
Myalgia	22.7	46.0
Adverse events within 7 days of administration from studies 2019n-501, -301, and -302; study participants aged ≥65 years
Adverse event reported	Dose 1 (%)	Dose 2 (%)
Local tenderness	33.0	54.9
Local erythema	0.8	5.2
Local swelling	0.7	5.7
Pain at injection site	19.3	40.5
Fatigue	16.3	28.6
Headache	15.3	23.6
Nausea or vomiting	3.7	5.1
Fever	0.5	1.9
Myalgia	12.3	26.4
Adapted from Product Monograph including Patient Medication Information: Nuvaxovid COVID-19 Vaccine: SARS-CoV-2 Vaccine (Recombinant protein, Adjuvanted).